Regimen | Dosing | Clinical considerations |
Rifamycin-based regimens¶ (preferred) | ||
Rifampin (daily for 4 months; 4R) |
| Better completion rates and less toxicity (relative to isoniazid monotherapy) |
IsoniazidΔ and rifampin (daily for 3 months; 3HR) |
| Better completion rates and less toxicity (relative to isoniazid monotherapy) |
IsoniazidΔ and rifapentine (weekly for 3 months; 3HP) |
| Better completion rates (relative to isoniazid monotherapy) Important side effects of 3HP include hypersensitivity or flu-like symptoms (eg, light headedness, dizziness, headache, nausea or vomiting, syncope, rash, or angioedema). For this reason, 3HP usually is administered via directly observed therapy, to facilitate side effect review and treatment withholding if needed. Self-administration of 3HP may be acceptable for patients who can reliably take their medications on schedule and inform their providers promptly of side effects (while withholding the next dose pending provider review). |
Isoniazid monotherapy regimens (alternative) | ||
IsoniazidΔ |
| Fewer drug interactions (relative to rifamycin-based regimens) |
* The regimens summarized in the table are for treatment of TB infection due to Mycobacterium tuberculosis presumed to be susceptible to isoniazid and rifamycins. For details regarding treatment of drug-resistant TB infection, refer to UpToDate topic on treatment of TB infection.
¶ In August 2020, the US Food and Drug Administration (FDA) announced detection of nitrosamine impurities in samples of rifampin and rifapentine. Refer to UpToDate topic on treatment of drug-susceptible pulmonary TB for further discussion.
Δ Peripheral neuropathy can occur among patients on TB infection regimens containing isoniazid due to interference with metabolism of pyridoxine and can be prevented with pyridoxine supplementation (25 to 50 mg daily). This is especially important for patients with conditions that can predispose to neuropathy (including diabetes, uremia, alcoholism, malnutrition, and HIV infection) as well as in the setting of pregnancy and seizure disorders. Pyridoxine should also be administered to infants of breastfeeding mothers receiving isoniazid.
◊ If isoniazid is used, we favor daily administration for 9 months given its established efficacy; daily treatment achieves greater adherence than intermittent therapy (ie, 3 times per week or 2 times per week). Isoniazid daily for 6 months (6H) provides some protection; in the setting of difficulty with adherence, providers may prefer to concentrate efforts in ensuring 6 months of therapy. This approach is favored by the World Health Organization. However, regimens shorter than 9 months should not be used for patients with fibrotic lesions on chest radiograph.
§ Twice-weekly regimens of isoniazid must be administered with directly observed therapy.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟